{"id":"duobrii","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site burning"},{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Teratogenicity risk (retinoid component)"}]},"_chembl":null,"_dailymed":{"setId":"b3f0cdc0-69fd-43d1-baf2-d776a3a20715","title":"DUOBRII (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION [BAUSCH HEALTH US, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Halobetasol propionate works as a Class I (super-potent) topical corticosteroid by binding glucocorticoid receptors to suppress inflammatory cytokines and immune cell infiltration. Tazarotene is a third-generation retinoid that binds retinoic acid receptors to promote keratinocyte differentiation and reduce hyperproliferation. The combination provides synergistic anti-inflammatory and anti-proliferative effects.","oneSentence":"Duobrii is a fixed-dose combination of halobetasol propionate (a potent topical corticosteroid) and tazarotene (a retinoid) that reduces inflammation and normalizes skin cell differentiation in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:06.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT05203315","phase":"PHASE3","title":"Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults","status":"COMPLETED","sponsor":"Austin Institute for Clinical Research","startDate":"2022-01-13","conditions":"Plaque Psoriasis","enrollment":21},{"nctId":"NCT04720105","phase":"PHASE4","title":"Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-11-19","conditions":"Palmoplantar Psoriasis, Plaque Psoriasis","enrollment":22},{"nctId":"NCT05282771","phase":"EARLY_PHASE1","title":"A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2021-04-16","conditions":"Plaque Psoriasis","enrollment":402},{"nctId":"NCT02785172","phase":"PHASE2","title":"Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-04","conditions":"Psoriasis","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Halobetasol propionate 0.01%/tazarotene 0.045% lotion","HP/TAZ","halobetasol propionate and tazarotene"],"phase":"marketed","status":"active","brandName":"Duobrii®","genericName":"Duobrii®","companyName":"Icahn School of Medicine at Mount Sinai","companyId":"icahn-school-of-medicine-at-mount-sinai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Duobrii is a fixed-dose combination of halobetasol propionate (a potent topical corticosteroid) and tazarotene (a retinoid) that reduces inflammation and normalizes skin cell differentiation in psoriasis. Used for Plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}